LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of “Buy” by Analysts

LifeMD, Inc. (NASDAQ:LFMD) has been given a consensus recommendation of “Buy” by the five analysts that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued a report on the stock in the last year is $12.40.

Several research analysts have recently commented on LFMD shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of LifeMD in a research note on Monday, November 11th. Finally, B. Riley initiated coverage on LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 target price for the company.

LifeMD Price Performance

NASDAQ:LFMD opened at $6.59 on Wednesday. LifeMD has a 52 week low of $3.99 and a 52 week high of $12.88. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.78 and a current ratio of 0.83. The firm’s 50-day simple moving average is $5.16 and its 200 day simple moving average is $6.02. The firm has a market cap of $285.41 million, a price-to-earnings ratio of -10.30 and a beta of 1.23.

Institutional Trading of LifeMD

Several large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in LifeMD by 251.0% during the first quarter. Russell Investments Group Ltd. now owns 64,927 shares of the company’s stock valued at $667,000 after purchasing an additional 46,428 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of LifeMD by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after purchasing an additional 128,701 shares in the last quarter. Ancora Advisors LLC increased its stake in shares of LifeMD by 97.8% in the 1st quarter. Ancora Advisors LLC now owns 137,760 shares of the company’s stock valued at $1,416,000 after purchasing an additional 68,110 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of LifeMD during the 1st quarter worth $249,000. Finally, Calamos Advisors LLC bought a new stake in shares of LifeMD during the 2nd quarter worth $394,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.